Skip to main content

Table 2 Odds ratios for early response to treatment measured by fold change in C6M from baseline to week 4

From: Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab

Response (week 16)

ΔC6Mw4

TCZ4 + MTX

TCZ8 + MTX

Placebo + MTX

OR

CI lower

CI upper

p

p.adj

OR

CI lower

CI upper

p

p.adj

OR

CI lower

CI upper

p

p.adj

Early non-responder

 Unadjusted

1.27

0.83

1.99

0.279

0.348

1.50

0.99

2.29

0.058

0.115

0.77

0.51

1.13

0.188

0.269

 Adjusted

1.28

0.83

2.03

0.267

0.334

1.52

0.99

2.36

0.059

0.117

0.76

0.50

1.13

0.182

0.261

DAS remission (< 2.6)

 Unadjusted

0.74

0.40

1.38

0.345

0.383

0.44

0.26

0.70

0.001

0.011

-

-

-

-

-

 Adjusted

0.77

0.43

1.38

0.390

0.433

0.41

0.24

0.66

< 0.001

0.005

-

-

-

-

-

DAS reduction (< 3.2)

 Unadjusted

0.67

0.41

1.05

0.085

0.141

0.59

0.39

0.86

0.008

0.038

-

-

-

-

-

 Adjusted

0.67

0.42

1.06

0.091

0.152

0.52

0.34

0.77

0.002

0.008

-

-

-

-

-

ACR50

 Unadjusted

0.62

0.40

0.95

0.031

0.076

0.64

0.43

0.93

0.021

0.071

0.86

0.46

1.63

0.635

0.635

 Adjusted

0.62

0.40

0.96

0.035

0.088

0.62

0.42

0.89

0.012

0.041

0.86

0.45

1.63

0.634

0.634

  1. Adjusted for sex, age, and BMI
  2. Odds ratio of response per 2-fold increase in ratio from baseline in C6M, a p-value < 0.05 was considered statistically significant